SecBot SecBot
8-K ·Filed May 15, 2026

ANVS

Annovis Bio, Inc.
MIXED
Impact 5/10
Horizonmonths Processed6mo ago SEC0001104659-26-062451
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The clinical progress is positive but expected; cash runway remains tight despite the recent $10M offering. Watch for enrollment completion and top-line data in early 2027, which are the primary catalysts. The increased loss rate keeps dilution risk alive.

DirectionMixed
Confidencemedium
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighted strong enrollment progress in its pivotal Phase 3 Alzheimer's trial (85% enrolled) and Parkinson's open-label extension study (40% enrolled), along with a positive DSMB recommendation. The clinical milestones support the NDA timeline but financial deterioration is a concern.

Key Financial Metrics

EPS
−$0.63
Revenue
$0.00

Key Facts

  • Phase 3 AD trial enrollment at 85%; full enrollment on track for summer 2026
  • PD OLE study enrollment at 40%; full enrollment expected Q4 2026
  • Positive DSMB recommendation for buntanetap safety at 6 months
  • Net loss per share widened to $0.63 from $0.32 in Q1 2025
  • Cash and equivalents $14.2M as of March 31, 2026, plus $10M April direct offering
  • NDA submission for symptomatic AD treatment expected early 2027

Financial Impact

Net loss increased to $17.6M from $5.5M year-over-year; cash burn accelerated due to Phase 3 trial costs

net loss per sharecash and equivalentsoperating expenses

Risk Factors

  • Clinical trial failure or data miss could devastate stock
  • Cash burn may require additional dilutive financing before data readout
  • Regulatory path for NDA uncertain until Phase 3 results

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-062451
Document: tm2614822d1_8k.htm0001104659-26-062451
Document: 0001104659-26-062451-index-headers.html0001104659-26-062451
Document: 0001104659-26-062451-index.html0001104659-26-062451
Document: 0001104659-26-062451.txt0001104659-26-062451
8-K Data (Synthetic)0001104659-26-062451

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026